Literature DB >> 2162499

The spectrum of neurologic disease associated with anti-GM1 antibodies.

S A Sadiq1, F P Thomas, K Kilidireas, S Protopsaltis, A P Hays, K W Lee, S N Romas, N Kumar, L van den Berg, M Santoro.   

Abstract

We compared anti-GM1 IgM antibody titers in patients with various neurologic diseases and in normal subjects. We found increased titers in patients with lower motor neuron disease, sensorimotor neuropathy, or motor neuropathy with or without multifocal conduction block. In patients with other diseases, titers are similar to those in normal individuals, suggesting that anti-GM1 antibody levels are not increased nonspecifically after neural injury or inflammatory diseases. Anti-GM1 antibodies in many of the patients occur as monoclonal gammopathies, predominantly of lambda light-chain type, but the antibodies are sometimes polyclonal with normal or increased serum IgM concentrations. Most of the anti-GM1 antibodies appear to react with the Gal(beta 1-3)GalNAc epitope which is shared with asialo-GM1 and GD1b, but in some patients the antibodies are more specific for GM1 and associated with motor neuropathy. Patients with motor or sensorimotor peripheral neuropathy or lower motor neuron disease should be tested for anti-GM1 antibodies or anti-Gal(beta 1-3)GalNAc antibodies, as therapeutic reduction in antibody concentrations was reported to result in clinical improvement in some patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2162499     DOI: 10.1212/wnl.40.7.1067

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  29 in total

1.  Development of amyotrophic lateral sclerosis in the course of systemic lupus erythematosus.

Authors:  X Forns; X Bosch; F Graus; M Navarro; J Font
Journal:  Clin Rheumatol       Date:  1992-12       Impact factor: 2.980

Review 2.  Multifocal motor neuropathy.

Authors:  E Nobile-Orazio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

Review 3.  Gangliosides and glycosphingolipids of peripheral nervous system myelins--a minireview.

Authors:  K Ogawa-Goto; T Abe
Journal:  Neurochem Res       Date:  1998-03       Impact factor: 3.996

Review 4.  Motor neuron disease.

Authors:  P N Leigh; K Ray-Chaudhuri
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-08       Impact factor: 10.154

5.  IgM ganglioside GM1 antibodies in patients with autoimmune disease or neuropathy, and controls.

Authors:  A S Bansal; B Abdul-Karim; R A Malik; P Goulding; R S Pumphrey; A J Boulton; P L Holt; P B Wilson
Journal:  J Clin Pathol       Date:  1994-04       Impact factor: 3.411

Review 6.  Antiglycolipid antibodies in peripheral neuropathy: fact or fiction?

Authors:  H J Willison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

7.  Inflammatory cells in the peripheral nervous system in motor neuron disease.

Authors:  H Kerkhoff; D Troost; E S Louwerse; M van Dijk; H Veldman; F G Jennekens
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

8.  Anti-GM1 antibodies in patients with Guillain-Barré syndrome.

Authors:  L H van den Berg; J Marrink; A E de Jager; H J de Jong; G W van Imhoff; N Latov; S A Sadiq
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-01       Impact factor: 10.154

9.  A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis.

Authors:  A Stevens; M Weller; H Wiethölter
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-04       Impact factor: 10.154

10.  Experimental autoimmune neuropathy with anti-GM1 antibodies and immunoglobulin deposits at the nodes of Ranvier.

Authors:  F P Thomas; W Trojaborg; C Nagy; M Santoro; S A Sadiq; N Latov; A P Hays
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.